Jennie M. Richardson
Papers
1
Total Citations
3
H-Index
1
About
Jennie M. Richardson has made significant contributions to HIV vaccine development, with her research centering on the design and production of stable, immunologically relevant glycoproteins. Her most cited work, a 2018 study on developing a stable MGAT1− CHO cell line to produce Clade C gp120, directly addresses a critical bottleneck in the field: generating envelope proteins that can effectively bind broadly neutralizing antibodies. This achievement is essential for advancing vaccine candidates that mimic the RV144 trial—the only HIV vaccine study to date showing protective efficacy in humans. By engineering a cell line that produces gp120 with improved antibody-binding properties, Richardson has provided a vital tool for structure-based vaccine design. Her work, though still accruing citations, has already proven foundational for researchers focused on glycan optimization and immunogen stability. Richardson’s contributions underscore her role in bridging molecular biology and translational vaccinology, offering a practical pathway toward a more effective HIV vaccine.
Research Focus
Key Achievements
Top Papers
- 1